AIGEN Sciences

AIGEN Sciences Inc. operates in the pharmaceutical and biotechnology sector, focusing on AI-driven drug discovery. The company leverages its award-winning AI platform to transform traditional drug discovery processes, which are often costly and inefficient, into rapid and efficient methodologies. This approach aims to increase the success rates of drugs in clinical phases by directly discovering high-potency drugs that target cellular activity with minimal off-target effects and toxicity. AIGEN Sciences serves pharmaceutical companies and research institutions looking to enhance their drug development pipelines. The business model revolves around providing access to its AI platform and collaborating on drug development projects, generating revenue through partnerships and licensing agreements. As a spin-off from Korea University's DMIS Lab, AIGEN Sciences benefits from a strong academic foundation and expertise in computer science and bioinformatics. The company is supported by grants, such as those from the Korea Drug Development Fund (KDDF), which further bolster its research and development capabilities.

Keywords: AI, drug discovery, biotechnology, pharmaceutical, clinical success, efficiency, toxicity reduction, partnerships, licensing, Korea.